Mathieu Charv News Today

Lyon, France – 29 April 2024 – 6pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31...

On Wednesday morning, Theranexus shares posted one of the biggest rises on the Paris market in sustained volumes, following the announcement of promising results from a study in the juvenile form of...

Theranexus, a biopharmaceutical company specializing in rare neurological diseases, announces the appointment of Mathieu Charvériat as Chairman of the Board of Directors, in addition to his current...

Presentation at the International Congress on Neuronal Ceroid Lipofuscinoses NCL2023 Lyon, France – Austin, Texas, United States – 29 September 2023 – 7.30am – CET – Theranexus, a...

THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS Lyon, France – 28 September 2023 – 6pm CEST – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological...

Reduction of neurofilaments, a biomarker of neuronal death, after 6 months of treatment Stabilization of motor symptoms for treated patients in comparison to the decline expected with the... | June 14, 2023

Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure

Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the ...

Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions,The FDA confirmed that this sole Phase III trial would secure Batten-1

This press release updates an earlier issuance with updated language throughout.Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor